At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06160 BEIGENE
Trading 06-18 10:39:57
162.400
+5.000
+3.18%
High165.200Low157.000Vol1.41M
Open157.400D1 Closing157.400Amplitude5.21%
Mkt Cap250.26BTradable Cap231.58BTotal Shares1.54B
T/O227.57MT/O Rate0.10%Tradable Shares1.43B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜BeiGene Rises 3.05% in Regular Trading, Tevimbra Esophageal Cancer Application Accepted by FDA
Market Focus  ·  26 minutes ago
Movement Alert｜BeiGene Rises 3.05% in Regular Trading, Tevimbra Esophageal Cancer Application Accepted by FDA
BeOne Medicines (formerly BeiGene) Releases 2026 Company Information Sheet, Details Swiss Redomicile, 16 HKEX Waivers and Ongoing U.S. GAAP Reporting
Bulletin Express  ·  06-11
BeOne Medicines (formerly BeiGene) Releases 2026 Company Information Sheet, Details Swiss Redomicile, 16 HKEX Waivers and Ongoing U.S. GAAP Reporting
Movement Alert｜BeOne Medicines Falls 4.17% in Regular Trading, Major Shareholder Reduction and Sustained Innovative Drug Sector Pressure
Market Focus  ·  06-11
Movement Alert｜BeOne Medicines Falls 4.17% in Regular Trading, Major Shareholder Reduction and Sustained Innovative Drug Sector Pressure
Movement Alert｜BeiGene Falls 3.13% in Regular Trading, Major Shareholder Reduction and Innovative Drug Sector Pressure Persist
Market Focus  ·  06-09
Movement Alert｜BeiGene Falls 3.13% in Regular Trading, Major Shareholder Reduction and Innovative Drug Sector Pressure Persist
BeiGene Grants 42,648 ADS Restricted Share Units to 381 Employees, Equal to 0.04% of Total Share Capital
Bulletin Express  ·  06-05
BeiGene Grants 42,648 ADS Restricted Share Units to 381 Employees, Equal to 0.04% of Total Share Capital
BEIGENE Announces Grant of Restricted Share Units
Stock News  ·  06-05
BEIGENE Announces Grant of Restricted Share Units
Movement Alert｜BeiGene Falls 3.1% in Regular Trading, Major Shareholder Reduction and Biotech Sector Weakness Weigh on Shares
Market Focus  ·  06-05
Movement Alert｜BeiGene Falls 3.1% in Regular Trading, Major Shareholder Reduction and Biotech Sector Weakness Weigh on Shares
Movement Alert｜BeiGene Rises 4.18% in Regular Trading, Technical Rebound After Consecutive Declines Combined With New Drug Approval Boost
Market Focus  ·  06-04
Movement Alert｜BeiGene Rises 4.18% in Regular Trading, Technical Rebound After Consecutive Declines Combined With New Drug Approval Boost
Movement Alert｜BeiGene Falls 3.02% in Regular Trading, Senior Executive Stake Reduction Combined with Prolonged Innovative Drug Sector Correction
Market Focus  ·  06-03
Movement Alert｜BeiGene Falls 3.02% in Regular Trading, Senior Executive Stake Reduction Combined with Prolonged Innovative Drug Sector Correction
Movement Alert｜BeOne Medicines Falls 3.85% in Regular Trading, Major Shareholder Reduction Coupled with Prolonged Biotech Sector Weakness
Market Focus  ·  06-02
Movement Alert｜BeOne Medicines Falls 3.85% in Regular Trading, Major Shareholder Reduction Coupled with Prolonged Biotech Sector Weakness
Movement Alert｜BeOne Medicines Falls 3.11% in Regular Trading, Major Shareholder Sells $190M Stake Amid Prolonged Biotech Sector Correction
Market Focus  ·  06-01
Movement Alert｜BeOne Medicines Falls 3.11% in Regular Trading, Major Shareholder Sells $190M Stake Amid Prolonged Biotech Sector Correction
Hong Kong Stock Connect Biotech Sector Extends Over 8-Month Slump, Key ETF Hits Record Low
Deep News  ·  05-28
Hong Kong Stock Connect Biotech Sector Extends Over 8-Month Slump, Key ETF Hits Record Low
Movement Alert｜BeiGene Declines 3.21% in Regular Trading, Trading at HK$175.1
Market Focus  ·  05-28
Movement Alert｜BeiGene Declines 3.21% in Regular Trading, Trading at HK$175.1
Market Chatter: China Approves 15 Domestic Innovative Drugs
MT Newswires Live  ·  05-28
Market Chatter: China Approves 15 Domestic Innovative Drugs
Movement Alert｜BeiGene Declines 3.07% in Regular Trading, Trading at HK$182.5
Market Focus  ·  05-27
Movement Alert｜BeiGene Declines 3.07% in Regular Trading, Trading at HK$182.5
BUZZ-J&T Global Express leads gain in newcomers to Hang Seng Index
Reuters  ·  05-26
BUZZ-J&T Global Express leads gain in newcomers to Hang Seng Index
Hang Seng Index Quarterly Review Boosts Industrial and Healthcare Sector Coverage; Six Stocks May Enter Southbound Trading
Stock News  ·  05-25
Hang Seng Index Quarterly Review Boosts Industrial and Healthcare Sector Coverage; Six Stocks May Enter Southbound Trading
Hang Seng Index Quarterly Review Results Announced: New Additions Include J&T Express, BeiGene, and CHALCO
Deep News  ·  05-22
Hang Seng Index Quarterly Review Results Announced: New Additions Include J&T Express, BeiGene, and CHALCO
Zhipu and MiniMax Poised for Inclusion in Hang Seng Tech Index
Deep News  ·  05-22
Zhipu and MiniMax Poised for Inclusion in Hang Seng Tech Index
Movement Alert｜BeiGene Rises 3.48% in Regular Trading, Q1 Earnings Beat Expectations as Multiple Banks Raise Outlook
Market Focus  ·  05-21
Movement Alert｜BeiGene Rises 3.48% in Regular Trading, Q1 Earnings Beat Expectations as Multiple Banks Raise Outlook
No data available

Introduction

Company Name.
BEIGENE
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Issue price:
--